ArticleNeurochemical research2025
Histamine H3 Receptor Antagonists Influence the Directional Growth of Type II Spiral Ganglion Neurites Within the Developing Cochlea of C57BL/6 Mice.
Article in Neurochemical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The histamine H3 receptor (H3R) is a crucial regulator of synaptic plasticity, neurotransmitter release, and neural signaling within the central nervous system. However, its role in the cochlea remains poorly understood, even though mast cells, a rich endogenous source of histamine, have recently been documented in the mammalian cochlea. This study examined H3R expression and localization in the postnatal day 4-5 (P4-5) C57BL/6 mouse cochlea and evaluated its functional consequences under antagonist treatment. RT-qPCR analysis showed significantly higher H3R mRNA levels in the modiolus compared to the organ of Corti and the lateral wall. Immunofluorescence staining confirmed H3R localization in hair cells (HCs) and spiral ganglion neurons (SGNs). Dissected cochlear explants exposed to two distinct H3R antagonists-ciproxifan and pitolisant-at concentrations of 10µM, 50µM, and 100µM, displayed different responses: ciproxifan induced dose-dependent HC loss. In contrast, pitolisant caused no loss of HC but led to stereociliary abnormalities at higher concentrations. Both antagonists disrupted type II SGN neurite projections, redirecting their normal basal-directed trajectory toward the apical region. These findings implicate H3R in maintaining cochlear structural integrity and guiding SGN neurite development during early postnatal maturation. Further investigation into H3R-mediated mechanisms may reveal new therapeutic targets for hearing preservation and repair.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.